BioVentures Investors, a Wellesley, Massachusetts-based venture capital firm focused on medtech, closed its fourth fund, at $87m.
Led by Marc Goldberg and Peter Feinstein, founders, Jeff Barnes, Managing Director and Partner, and Walter Gilbert as Senior Partner, Fund IV will invest in medical technology enterprises such as medical devices and diagnostics. It focuses on technology with the potential to provide important benefits to patients, physicians and healthcare institutions, as well as significant returns to investors.
Since its initial close, the fund has made four investments, including Locemia Solutions which was acquired by Eli Lilly.
Other investments include:
– Deep Vein Medical, expected to take its prosthetic venous valve into human trials next year;
– CoNextions Medical, a company whose system of simple and rapid tendon repair technology is expecting FDA marketing approval this year, and
– Endotronix, a digital health medtech company focused on advancing the treatment of heart failure.
To date, BioVentures Investors has raised more than $220 million in four funds, all focused on the commercial development of innovative healthcare technology.